ENTITY

PegBio (2565 HK)

36
Analysis
Health Care • China
PegBio Co., Ltd. is a biotechnology company focused on the discovery and development of innovative therapies for chronic diseases, particularly metabolic disorders. The company develops differentiated therapeutics for conditions such as type 2 diabetes mellitus, obesity, metabolic dysfunction-associated steatohepatitis (MASH), opioid-induced constipation (OIC), and congenital hyperinsulinemia. PegBio was founded in 2008 and is headquartered in Hangzhou, Zhejiang Province, China.
more
bearish•Medtide
•29 Jun 2025 16:18

Medtide (泰德医药) IPO Trading Update

​Medtide raises $65.5m in global offering, set to list on Hong Kong Stock Exchange June 30th. We provide an update prior to trading debut on Monday.

Logo
433 Views
Share
bearish•PegBio
•26 May 2025 20:58

PegBio IPO Trading Update

​PegBio raises $38m in global offering, set to list on HK Stock Exchange with retail investors holding majority of free float shares.

Logo
505 Views
Share
bearish•PegBio
•19 May 2025 14:31

PegBio 派格生物 IPO: A Hardsell but Mostly Done Deal

​China-based biotech company PegBio launches IPO in Hong Kong to raise up to US$39m, with demanding valuation but support from local government for...

Logo
852 Views
Share
•13 May 2025 10:58

Innogen (银诺医药) Pre-IPO First Take: Good News Is Also Bad News

Innogen, the leading Chinese company in the GLP-1 space, seeks to raise $100 million through Hong Kong listing, with focus on product pipeline and...

Logo
738 Views
Share
•05 May 2025 08:48

ECM Weekly (5 May 2025) - CATL, Chery, Ather, Drinda, Eco-Shop, Green Tea, DN Sol, Lotte Glo, Hanwha

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Logo
700 Views
Share
x